177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

September 1, 2032

Study Completion Date

September 1, 2033

Conditions

Oligometastatic Prostate CarcinomaProstate AdenocarcinomaRecurrent Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8

Interventions

DRUG

Lutetium Lu-177 PNT2002

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER